ArticleJCO oncology advances
Patient Reported Toxicity with Radiation Deintensification in HPV-Associated Oropharynx Cancer: ECOG-ACRIN E2399 and E1308.
Article in JCO oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundE2399 showed higher response rates and survival for human papillomavirus-associated (HPV+) oropharynx (OP) cancer than for HPV-negative OP cancer. E1308, a follow-up prospective phase II trial in HPV+ OP patients, hypothesized that reduced radiation (54Gy) may achieve comparable tumor control in patients who achieve a complete clinical response to induction chemotherapy, and that toxicities would be ameliorated.
methodsAcute and late toxicities for both E2399 and E1308 were recorded prospectively using a battery of patient reported outcomes (PROs). General QOL PROs utilized on E1308 included KATZ -ADL, BFI, IADL, Baecke, CHAMPS; HHC specific PROs were FACT-HN, and the VHNSSv2. E2399 used the FACT-HN. Toxicities were correlated with both IMRT dose (69.3Gy vs. 54Gy) used on E1308, and with IMRT technique utilized on E1308 versus 3D conformal RT used on E2399.
resultsRadiation dose reduction resulted in significant decreased toxicities as detected with VHNNSv2 and FACT-HN PRO instruments. The VHNSSv2 showed late symptoms are significantly reduced by lowering IMRT to 54Gy: eating solids (p = 0.011), liquids (p = 0.004), voice changes (p = 0.026), dry mouth (p=0.02), and neck and shoulder movements (p=0.03). FACT-HN showed less difficulty in eating solids at 6 months (p = 0.054), as well as voice strength and quality (p = 0.038). Comparing IMRT 69.3Gy to 3D RT 70Gy, the FACT-HN showed eating solids at 12 months (p = 0.0067) and greater ability to eat foods the patient liked (p = 0.0103).
conclusionBoth radiation dose reduction and utilizing IMRT decreased toxicities in a variety of QOL PROs. Head and neck specific PROs are more sensitive than qeneral PROs. Inter-instrument corroboration validates the FACT-HN and VHNSSv2 utility for treatment deintensification evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.